IMPAKT 2015: Sponsor Profiles

Gold sponsor


Roche logo

F. Hoffmann-La Roche Ltd.
4070 Basel

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Silver sponsor

Pfizer, Inc.


235 East 42nd Street
New York, NY 10017
Tel: 1-212-733-2323

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.  Our strong pipeline of biologics and small molecules is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers.

Participating sponsor

Lightpoint Medical

Lightpoint Logo

Cardinal Point
Park Road
WD3 1RE, Rickmansworth
United Kingdom
Tel: +44 (0)1923437673

Lightpoint Medical is an innovative, clinical-stage medical device company founded in 2012. The company has developed a groundbreaking surgical imaging technology based on Cerenkov Luminescence Imaging (CLI). CLI has the potential to detect cancer in real-time during surgery, and thereby reduce the need for repeat operations.

CLI enables optical detection of Positron Emission Tomography (PET) radiopharmaceuticals, combining the advantages of optical imaging (namely, low cost and small form factor) with the power of PET imaging (i.e., high diagnostic performance, and widespread availability of imaging agents).

Myriad Genetics GmbH

Myriad Logo

Leutschenbachstrasse 95
8050 Zurich
Tel: +41 44 939 91 44
Fax: +41 44 939 91 31

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.